Poultry Science Department, Mississippi State University, Mississippi State, MS.
Mississippi USDA-ARS Poultry Research Unit, Mississippi State, MS.
Poult Sci. 2017 Sep 1;96(11):3879-3884. doi: 10.3382/ps/pex196.
Mycoplasma gallisepticum (MG) is a bacterial pathogen that causes production losses in layer chickens. To combat MG, multiage layer facilities vaccinate pullets by either spray or eye-drop vaccination. The objective in this study was to evaluate the use of in ovo vaccination as a potential alternative for MG vaccination. Layer embryos at 18 d of incubation were either not-injected (control), or were hand-injected with either commercial Marek's disease vaccine diluent alone or with a high, medium, low, or very low dosage of a live attenuated strain F (FMG) vaccine suspended in the commercial diluent. Hatch success and residual egg embryonic mortality were determined after 23 d of incubation. Six hatched chicks per treatment were swabbed for the detection of FMG at 4 different sites (trachea, mouth and esophagus, yolk sac membrane, and the lumen of the duodenal loop) via real-time PCR. Embryos were found to be administered 106 CFU per dose in the high treatment, 104 CFU/dose in the medium treatment, 102 CFU/dose in the low treatment, and between 5.06 and 5.93 CFU/dose in the very low treatment. Hatch of embryonated eggs was decreased by the medium and high doses (P = 0.02). These embryos died while pipping. No FMG was detected in the control and diluent-injected chicks. In the FMG treatments, FMG was found in all sites and dosages, with a greater number of positive chicks found in the higher FMG dosage treatments. These findings indicate the potential practicality of vaccinating layer embryos with FMG by in ovo injection based on the observed hatch success at lower dosages. Also, once injected into the amnion, the bacteria are present in the upper respiratory and gastrointestinal tracts as well the yolk sac membrane and the small intestine of hatchlings. Future research will need to ascertain the effects of FMG administered by in ovo injection on posthatch immunity and mortality.
鸡败血支原体(MG)是一种导致蛋鸡生产损失的细菌病原体。为了防治 MG,多层鸡舍通过喷雾或滴眼接种疫苗对育雏鸡进行免疫。本研究的目的是评估卵内接种作为 MG 疫苗接种的潜在替代方法。在孵化 18 天的蛋鸡胚胎中,要么不注射(对照),要么手动注射商业马立克氏病疫苗稀释剂,或商业稀释剂中悬浮的高、中、低或极低剂量的活减毒 F 株(FMG)疫苗。孵化 23 天后,确定孵化成功率和残余卵胚胎死亡率。每个处理 6 只孵化的小鸡在 4 个不同部位(气管、口腔和食管、卵黄囊膜和十二指肠环管腔)通过实时 PCR 进行 FMG 检测。结果发现,高剂量组每个剂量接种 106 CFU,中剂量组 104 CFU/剂量,低剂量组 102 CFU/剂量,极低剂量组 5.06 到 5.93 CFU/剂量。中剂量和高剂量组的孵化率下降(P=0.02)。这些胚胎在破壳时死亡。对照和稀释剂注射组的小鸡未检测到 FMG。在 FMG 处理组中,所有部位和剂量均检测到 FMG,高剂量 FMG 处理组的阳性小鸡数量更多。这些发现表明,基于较低剂量观察到的孵化成功率,通过卵内注射用 FMG 对蛋鸡胚胎进行免疫接种具有潜在的实用性。此外,一旦注入羊膜腔,细菌就存在于上呼吸道和胃肠道以及卵黄囊膜和雏鸡的小肠中。未来的研究需要确定通过卵内注射给予 FMG 对孵化后免疫和死亡率的影响。